Vivos (RDGL) EBIT Growth (1y) (2011 - 2025)
Vivos (RDGL) EBIT Growth (1y) (2011 - 2025) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 183.06 Bn | 175.76 Bn | 6.27 Bn | -20.56% |
| 2 | Stryker | 128.66 Bn | 125.78 Bn | 3.81 Bn | 11.83% |
| 3 | Medtronic | 108.82 Bn | 99.60 Bn | 6.41 Bn | 30.43% |
| 4 | Boston Scientific | 68.43 Bn | 66.98 Bn | 3.61 Bn | 19.54% |
| 5 | Edwards Lifesciences | 48.29 Bn | 44.61 Bn | 1.29 Bn | 20.97% |
| 6 | GE HealthCare Technologies | 28.37 Bn | 26.08 Bn | 1.98 Bn | -18.12% |
| 7 | Dexcom | 28.29 Bn | 27.18 Bn | 750.30 Mn | 90.95% |
| 8 | Smith & Nephew | 26.89 Bn | 26.31 Bn | - | - |
| 9 | Koninklijke Philips | 25.43 Bn | 22.31 Bn | 2.07 Bn | 74.18% |
| 10 | Vivos | 26.71 Mn | 25.15 Mn | -3,105.00 | -65.57% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -65.57% |
| Sep 30, 2025 | 37.02% |
| Jun 30, 2025 | -29.19% |
| Mar 31, 2025 | -49.63% |
| Dec 31, 2024 | 29.80% |
| Sep 30, 2024 | -22.62% |
| Jun 30, 2024 | 42.88% |
| Mar 31, 2024 | -132.42% |
| Dec 31, 2023 | -33.61% |
| Sep 30, 2023 | -148.18% |
| Jun 30, 2023 | -16.11% |
| Mar 31, 2023 | 66.78% |
| Dec 31, 2022 | -223.04% |
| Sep 30, 2022 | -42.39% |
| Jun 30, 2022 | 57.52% |
| Mar 31, 2022 | -217.96% |
| Dec 31, 2021 | 26.02% |
| Sep 30, 2021 | -51.50% |
| Jun 30, 2021 | -1,343.08% |
| Mar 31, 2021 | -95.30% |